How to Help Your Patients Find Micafungin in Stock: A Provider's Guide

Access to IV antifungal therapy does not end when you write the prescription. For patients requiring outpatient or home micafungin therapy, the path from prescription to infusion involves multiple coordination points where things can go wrong. This guide provides infectious disease physicians, hospitalists, transplant specialists, and clinical pharmacists with practical workflows to ensure patients get uninterrupted micafungin access.

Understanding the Micafungin Access Landscape

Micafungin is only available as an IV medication and is not stocked at retail pharmacies. For patients transitioning from inpatient to outpatient care, access must be coordinated through one of these channels:

Hospital outpatient infusion centers: Patients come to the facility daily for IV administration. This is the most clinically monitored option but requires daily travel.

Home infusion pharmacy services: A specialty pharmacy delivers prepared IV medication to the patient's home, and a nurse or infusion technician administers it. This is the most convenient option for appropriate patients.

Community infusion centers: Freestanding infusion centers in the community, independent of hospital systems, that may stock and administer micafungin.

Workflow 1: Inpatient-to-Home Infusion Transition

The hospital discharge transition is the highest-risk moment for treatment interruption. Follow this workflow to minimize gaps:

Day of decision to discharge (D-3 to D-2): Notify the hospital case manager and social worker that the patient requires continuation of IV micafungin. Initiate insurance prior authorization for home infusion services immediately.

D-2: Hospital pharmacy or case manager contacts 2 to 3 home infusion pharmacies to confirm micafungin availability, supply lead time, and in-network status. Obtain confirmation from at least one pharmacy before proceeding.

D-1: Transmit the complete outpatient order including drug name, dose, frequency, diluent, infusion rate, and duration of therapy to the home infusion pharmacy. Arrange for a bridge supply of 1 to 2 days of micafungin from the inpatient pharmacy if any uncertainty remains about home pharmacy delivery timing.

Discharge day: Confirm the home infusion pharmacy has dispensed the first dose or that a nurse visit is scheduled for day one post-discharge. Provide the patient with the home infusion pharmacy's 24-hour contact number.

Workflow 2: Sourcing Micafungin When a Pharmacy Is Out of Stock

If your primary home infusion pharmacy reports a back order or supply gap, use this escalation pathway:

Ask the pharmacy what specific NDC is unavailable and whether an alternate manufacturer's product is available.

Contact your hospital pharmacy's purchasing department, which has access to drug wholesalers and GPO contracts that individual home infusion pharmacies may not.

Direct the patient to medfinder for providers, which contacts multiple pharmacies to identify which ones have micafungin in stock in the patient's area.

If supply cannot be confirmed within 24 hours, evaluate whether switching to an available echinocandin (caspofungin or anidulafungin) is clinically appropriate to avoid treatment interruption.

What to Include in Your Outpatient Micafungin Order

A complete home infusion micafungin order must include the following elements to avoid delays at the pharmacy level:

Drug: Micafungin sodium for injection (generic accepted)

Dose: (e.g., 100 mg for candidemia, 150 mg for esophageal candidiasis, 50 mg for HSCT prophylaxis)

Diluent: 250 mL 0.9% sodium chloride or 5% dextrose in water

Rate: Infuse over 60 minutes (do not co-infuse with other medications)

Frequency: Once daily

Duration: Specify end date or duration in days

HCPCS code: J2248 for billing purposes

Diagnosis code (ICD-10): B37.7 (candidemia), B37.81 (candidal esophagitis), or applicable code

Setting Patient Expectations

Patients and families need to understand the following before discharge: IV antifungal treatment requires a functioning IV access device (PICC line, central line, or port) that will be maintained by the home infusion nurse; treatment cannot be paused or delayed without medical consultation; and infusion reactions (rash, flushing, fever) should be reported immediately. Educate patients to call their infusion pharmacy immediately if doses are missed due to supply or delivery issues.

For the full clinical shortage briefing, see our article on micafungin shortage: what providers need to know in 2026.